Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Journal of Nutrition
Erschienen in: European Journal of Nutrition 3/2018

05.09.2017 | Review

Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis

verfasst von: Fabiana de Faria Ghetti, Daiane Gonçalves Oliveira, Juliano Machado de Oliveira, Lincoln Eduardo Villela Vieira de Castro Ferreira, Dionéia Evangelista Cesar, Ana Paula Boroni Moreira

Erschienen in: European Journal of Nutrition | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Nonalcoholic steatohepatitis (NASH) is characterized by the presence of steatosis, inflammation, and ballooning degeneration of hepatocytes, with or without fibrosis. The prevalence of NASH has increased with the obesity epidemic, but its etiology is multifactorial. The current studies suggest the role of gut microbiota in the development and progression of NASH. The aim is to review the studies that investigate the relationship between gut microbiota and NASH. These review also discusses the pathophysiological mechanisms and the influence of diet on the gut–liver axis.

Result

The available literature has proposed mechanisms for an association between gut microbiota and NASH, such as: modification energy homeostasis, lipopolysaccharides (LPS)–endotoxemia, increased endogenous production of ethanol, and alteration in the metabolism of bile acid and choline. There is evidence to suggest that NASH patients have a higher prevalence of bacterial overgrowth in the small intestine and changes in the composition of the gut microbiota. However, there is still a controversy regarding the microbiome profile in this population. The abundance of Bacteroidetes phylum may be increased, decreased, or unaltered in NASH patients. There is an increase in the Escherichia and Bacteroides genus. There is depletion of certain taxa, such as Prevotella and Faecalibacterium.

Conclusion

Although few studies have evaluated the composition of the gut microbiota in patients with NASH, it is observed that these individuals have a distinct gut microbiota, compared to the control groups, which explains, at least in part, the genesis and progression of the disease through multiple mechanisms. Modulation of the gut microbiota through diet control offers new challenges for future studies.
Literatur
1.
2.
3.
Browning JD, Szczepaniak LS, Dobbins R et al (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40(6):1387–1395CrossRef
4.
Wanless IR, Lentz JS (1990) Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12(5):1106–1110CrossRef
5.
Losekann A, Weston AC, Mattos AA et al (2015) Nonalcoholic steatohepatitis (NASH): risk factors in morbidly obese patients. Int J Mol Sci 16(10):25552–25559CrossRef
6.
Ekstedt M, Franzén LE, Mathiesen UL et al (2006) Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44(4):865–873CrossRef
7.
Bacon BR, Farahvash MJ, Janney CG et al (1994) Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107(4):1103–1109CrossRef
8.
White DL, Kanwal F, El-Serag HB (2012) Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10(12):1342–1359CrossRef
9.
Orman ES, Barritt AS, Wheeler SB et al (2013) Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death. Liver Transpl 19(1):59–68CrossRef
10.
Jumpertz R, Le DS, Turnbaugh PJ et al (2011) Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 94(1):58–65CrossRef
11.
Backhed F, Ding H, Wang T et al (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci 101(4):15718–15723CrossRef
12.
Csak T, Ganz M, Pespisa J et al (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 54(1):133–144CrossRef
13.
Miura K, Kodama Y, Inokuchi S et al (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 139(1):323–334CrossRef
14.
Wigg AJ, Roberts-Thomson IC, Dymock RB et al (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor á in the pathogenesis of nonalcoholic steatohepatitis. Gut 48(2):206–211CrossRef
15.
Miele L, Valenza V, La Torre G et al (2009) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49(6):1877–1887CrossRef
16.
Mouzaki M, Comelli EM, Arendt BM (2013) Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58(1):120–127CrossRef
17.
18.
Zhu L, Baker SS, Gill C et al (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57(2):601–609CrossRef
19.
Preidis GA, Versalovic J (2009) Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136(6):2015–2031CrossRef
20.
Day CP, James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114(4):842–845CrossRef
21.
Donnelly KL, Smith CI, Schwarzenberg SJ et al (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115(5):1343–1351CrossRef
22.
Mittendorfer B, Yoshino M, Patterson BW et al (2016) VLDL triglyceride kinetics in lean, overweight, and obese men and women. J Clin Endocrinol Metab 101:4151–4160CrossRef
23.
Pessayre D, Berson A, Fromenty B et al (2001) Mitochondria in steatohepatitis. Semin Liver Dis 21:57–69CrossRef
24.
Leclerq IA, Farrell GC, Fiels J et al (2000) CYP2EI and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Investig 105:1067–1075CrossRef
25.
Parola M, Pinzani M, Casini A et al (1993) Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1(I) gene expression in human liver fat-storing cells. Biochim Biophys Res Commun 194:1044–1050CrossRef
26.
Jaeschke H, Wang Y, Essani NA (1996) Reactive oxygen species activate the transcription factor NF-kB in the liver by induction of lipid peroxidation (abstr). Hepatology 24:238ACrossRef
27.
Lee KS, Buck M, Houglum K, Chojkier M (1995) Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Investig 96:2461–2468CrossRef
28.
Wang B, Jiang X, Cao M et al (2016) Altered fecal microbiota correlates with liver biochemistry in nonobese patients with nonalcoholic fatty liver disease. Sci Rep 6:32002. doi:10.​1038/​srep32002 CrossRef
29.
Takaki A, Kawai D, Yamamoto K (2013) Multiple hits, including oxidative stress, as pathogenesis and treatment target in nonalcoholic steatohepatitis (NASH). Int J Mol Sci 14:20704–20728. doi:10.​3390/​ijms141020704 CrossRef
30.
Yamaguchi K, Yang L, McCall S et al (2007) Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45(6):1366–1374CrossRef
31.
Tilg H, Moschen AR (2010) Evolution of Inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52(5):1836–1846CrossRef
32.
Feldstein AE, Werneburg NW, Canbay A et al (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40:185–194CrossRef
33.
Mari M, Caballero F, Colell A et al (2006) Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 4:185–198CrossRef
34.
35.
36.
Xue L, He J, Gao N et al (2017) Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep 7:45176. doi:10.​1038/​srep45176 CrossRef
37.
Erejuwa OO, Sulaiman SA, Wahab MAS (2014) Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci 15(3):4158–4188CrossRef
38.
Sender R, Fuchs S, Milo R (2016) Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 164:337–340CrossRef
39.
Rajilic-Stojanovic M (2013) Function of the microbiota. Best Pract Res Clin Gastroenterol 27:5–16CrossRef
40.
Zhernakova A, Kurilshikov A, Bonder MJ et al (2016) Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352(6285):565–569. doi:10.​1126/​science.​aad3369 CrossRef
41.
Lepage P, Leclerc MC, Joossens M et al (2013) A metagenomic insight into our gut’s microbiome. Gut 62:146–158CrossRef
42.
43.
Scheithauer TPM, Dallinga-Thie GM, De Vos WM et al (2016) Causality of small and large intestinal microbiota in weight regulation and insulin resistance. Mol Metab 5:759–770CrossRef
44.
Yatsunenko T, Rey FE, Manary MJ et al (2012) Human gut microbiome viewed across age and geography. Nature 486(7402):222–227. doi:10.​1038/​nature11053
45.
46.
Nadal I, Santacruz A, Marcos A et al (2009) Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes (Lond) 33:758–767CrossRef
47.
Turnbaugh PJ, Ley RE, Mahowald MA et al (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122):1027–1031CrossRef
48.
49.
Boursier J, Mueller O, Barret M et al (2016) The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63(3):764–775CrossRef
50.
Bäckhed F, Manchester JK, Semenkovich CF et al (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. PNAS 104(3):979–984CrossRef
51.
Le Roy T, Llopis M, Lepage P et al (2013) Intestinal microbiota determines development of nonalcoholic fatty liver disease in mice. Gut 62:1787–1794CrossRef
52.
Henao-Mejia J, Elinav E, Jin C et al (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482(7384):179–185CrossRef
53.
54.
Cani PD, Amar J, Iglesias MA et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7):1761–1772CrossRef
55.
De Minicis S, Rychlicki C, Agostinelli L et al (2014) Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 59:1738–1749CrossRef
56.
Osman N, Adawi D, Ahrne S et al (2007) Endotoxin- and d-galactosamine-induced liver injury improved by the administration of Lactobacillus, Bifidobacterium and blueberry. Dig Liver Dis 39:849–856CrossRef
57.
Xing HC, Li LJ, Xu KJ et al (2006) Protective role of supplement with foreign Bifidobacterium and Lactobacillus in experimental hepatic ischemia–reperfusion injury. J Gastroenterol Hepatol 21:647–656CrossRef
58.
Ueyama J, Nadai M, Kanazawa H et al (2005) Endotoxin from various gram-negative bacteria has differential effects on function of hepatic cytochrome P450 and drug transporters. Eur J Pharmacol 510:127–134CrossRef
59.
Drenick EJ, Fisler J, Johnson D (1982) Hepatic steatosis after intestinal by-pass. Prevention and reversal by metronidazole irrespective of protein-calorie malnutricion. Gastroenterology 82(3):535–548
60.
Shanab AA, Scully P, Crosbie O et al (2011) Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 56(5):1524–1534CrossRef
61.
Bures J, Cyrany J, Kohoutova D et al (2010) Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 16:2978–2990CrossRef
62.
Corazza GR, Menozzi MG, Strocchi A et al (1990) The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology 98(2):302–309CrossRef
63.
Saad RJ, Chey WD (2014) Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. Clin Gastroenterol Hepatol 12:1964–1972CrossRef
64.
Krajicek EJ, Hansel SL (2016) Small intestinal bacterial overgrowth: a primary care review. Mayo Clin Proc 91(12):1828–1833CrossRef
65.
Khoshini R, Dai SC, Lezcano S (2008) A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 53(6):1443–1454CrossRef
66.
Erdogan A, Lee YY, Badger C et al (2014) What is the optimal threshold for an increase in hydrogen and methane levels with glucose breath test (GBT) for detection of small intestinal bacterial overgrowth (SIBO)? Gastroenterology 146(5):S532CrossRef
67.
Lin EC, Massey BT (2016) Scintigraphy demonstrates high rate of false-positive results from glucose breath tests for small bowel bacterial overgrowth. Clin Gastroenterol Hepatol 14(2):203–208CrossRef
68.
Zoetendal EG, Raes J, Van Den Bogert B et al (2012) The human small intestinal microbiota is driven by rapid uptake and conversion of simple carbohydrates. ISME J 6:1415–1426. doi:10.​1038/​ismej.​2011.​212 CrossRef
69.
Del Chierico F, Nobili V, Vernocchi P et al (2016) Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by na integrated meta-omics-based approach. Hepatology. doi:10.​1002/​hep.​28572
70.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI et al (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444(7122):1022–1023CrossRef
71.
Wieland A, Frank DN, Harnke B et al (2015) Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 42:1051–1063CrossRef
72.
Benhamed F, Denechaud FD, Lemoine M et al (2012) The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Investig 122(6):2176–2194. doi:10.​1172/​JCI41636 CrossRef
73.
Wolever TM, Brighenti F, Royall D et al (1989) Effect of rectal infusion of short chain fatty acids in human subjects. Am J Gastroenterol 84:1027–1033
74.
75.
McNeil NI (1984) The contribution of the large intestine to energy supplies in man. Am J Clin Nutr 39:338–342CrossRef
76.
Moreira APB, Teixeira TFS, Ferreira AB et al (2012) Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 108(5):801–809CrossRef
77.
Lu Y, Fan C, Li P et al (2016) Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein coupled receptors and gut microbiota. Sci Rep 6:37589. doi:10.​1038/​srep37589 CrossRef
78.
Anastasovska J, Arora T, Canon GJs et al (2012) Fermentable carbohydrate alters hypothalamic neuronal activity and protects against the obesogenic environment. Obesity (Silver Spring) 20(5):1016–1023CrossRef
79.
Cani PD, Possemiers S, Van de Wiele T et al (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58(8):1091–1103CrossRef
80.
Delzenne NM, Cani PD, Neyrinck AM (2007) Modulation of glucagonlike peptide 1 and energy metabolism by inulin and oligofructose:experimental data. J Nutr 137(11 Suppl):2547S–2551SCrossRef
81.
Le Poul E, Loison C, Struyf S et al (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem 278:25481–25489CrossRef
82.
Stoddart LA, Smith NJ, Milligan G (2008) International union of pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol Rev 60:405–417CrossRef
83.
Milligan G, Stoddart LA, Smith NJ (2009) Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol 158:146–153CrossRef
84.
Samuel BS, Shaito A, Motoike T et al (2008) Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. PNAS 5(430):16767–16772CrossRef
85.
Ge H, Li X, Weiszmann J et al (2008) Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 149(9):4519–4526CrossRef
86.
87.
88.
89.
Erridge C, Attina T, Spickett CM et al (2007) A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 86(5):1286–1292CrossRef
90.
Cani PD, Bibiloni R, Knauf C et al (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57:1470–1481CrossRef
91.
Manco M, Putignani L, Bottazzo GF (2010) Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 31(6):817–844CrossRef
92.
Ye D, Li FY, Lam KS et al (2012) Toll-like receptor-4 mediates obesity-induced nonalcoholic steatohepatitis through activation of X-box binding protein-1 in mice. Gut 61(7):1058–1067CrossRef
93.
Su GL (2002) Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol 283:G256–G265CrossRef
94.
95.
Alisi A, Manco M, Devito R et al (2010) Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. JPGN 50:645–649
96.
Luyendyk JP, Maddox JF, Green CD et al (2004) Role of hepatic fibrin in idiosyncrasy-like liver injury from lipopolysaccharide-ranitidine coexposure in rats. Hepatology 40:1342–1351CrossRef
97.
Targher G, Bertolini L, Scala L et al (2007) Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 30:e31–e32. doi:10.​2337/​dc07-0109 CrossRef
98.
Ruiz AG, Casafont F, Crespo J et al (2007) Lipopolysaccharide-binding protein plasma levels in liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of nonalcoholic steatohepatitis. Obes Surg 17(10):1374–1380CrossRef
99.
Yang SQ, Lin HZ, Lane MD et al (1997) Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 94:2557–2562CrossRef
100.
Kirsch R, Clarkson V, Verdonk RC et al (2006) Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J Gastroenterol Hepatol 21(1 Pt 1):174–182CrossRef
101.
Thuy S, Ladurner R, Volynets V et al (2008) Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 138(8):1452–1455CrossRef
102.
103.
Brun P, Castagliuolo I, Di Leo V et al (2007) Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 292:G518–G525CrossRef
104.
Farhadi A, Gundlapalli S, Shaikh M et al (2008) Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in nonalcoholic steatohepatitis. Liver Int 28:1026–1033CrossRef
105.
Cope K, Risby T, Diehl AM (2000) Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 119:1340–1347CrossRef
106.
Nair S, Cope K, Terence RH et al (2001) Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 96(4):1200–1204CrossRef
107.
108.
Nosova T, Jokelainen K, Kaihovaara P et al (1996) Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine. Alcohol Alcohol 31(6):555–564CrossRef
109.
McManus IR, Contag AO, Olson RE (1960) Characterization of endogenous ethanol in the mammal. Science 131:102–103CrossRef
110.
Baraona E, Julkunen R, Tannenbaum L et al (1986) Role of intestinal bacterial overgrowth in ethanol production and metabolism in rats. Gastroenterology 90:103–110CrossRef
111.
Hunnisett A, Howard J, Davies S (1990) Gut fermentation (or autobrewery) syndrome. A new clinical test with initial observations and discussion of clinical and biological implications. J Nutr Med 1:33–38. doi:10.​3109/​1359084900900313​2
112.
Böck A, Sawers G (1996) Fermentation. In: Neidhardt FC, Curtiss R III, Ingraham JL, Lin ECC, Low KB, Magasanik B, Reznikoff B, Riley M, Schaechter M, Umbarger HE (eds) Escherichia coli and Salmonella typhimurium: cellular and molecular biology, 2nd edn. ASM Press, Washington, DC, pp 262–282
113.
Elshaghabee FMF, Bockelmann W, Meske D et al (2016) Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions. Front Microbiol 7:47. doi:10.​3389/​fmicb.​2016.​00047 CrossRef
114.
Volynets V, Küper MA, Strahl S et al (2012) Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci 57:1932–1941CrossRef
115.
Collins MD, Samelis J, Metaxopoulos J et al (1993) Taxonomic studies on some leuconostoc-like organisms from fermented sausages: description of a new genus Weissella for the Leuconostoc paramesenteroides group of species. J Appl Bacteriol 75:595–603. doi:10.​1111/​j.​1365-2672.​1993.​tb01600.​x CrossRef
116.
117.
Buckel W (1999) Anaerobic energy metabolism. In: Lengeler JW, Drews G, Schlegel HG (eds) Biology of the prokaryotes. Georg Thieme Verlag, Stuttgart, pp 278–326
118.
Lieber C (1991) Hepatic, metabolic and toxic effect of ethanol. Alcohol Clin Exp Res 15:573–592CrossRef
119.
Gustot T, Lemmers A, Moreno C et al (2006) Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology 43:989–1000CrossRef
120.
Forsyth CB, Tang Y, Shaikh M et al (2011) Role of snail activation in alcohol-induced iNOS-mediated disruption of intestinal epithelial cell permeability. Alcohol Clin Exp Res 35(9):1635–1643
121.
Yuan L, Bambha K (2015) Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol 7(28):2811–2818CrossRef
122.
Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241–259CrossRef
123.
Dawson PA, Karpen SJ (2015) Intestinal transport and metabolism of bile acids. J Lipid Res 56:1085–1099CrossRef
124.
125.
126.
Claudel T, Staels B, Kuipers F (2005) The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 25:2020–2031CrossRef
127.
Thomas C, Gioiello A, Noriega L et al (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10(3):167–177CrossRef
128.
Sayin SI, Wahlström A, Felin J et al (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17:225–235CrossRef
129.
130.
Aranha MM, Cortez-Pinto H, Costa A et al (2008) Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 20(6):519–525CrossRef
131.
Kalhan S, Guo L, Edmison J et al (2011) Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 60(3):404–413CrossRef
132.
Faubion WA, Guicciardi ME, Miyoshi H et al (1999) Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Faz. J Clin Invest 103:137–145CrossRef
133.
Parlesak A, Schaeckeler S, Moser L et al (2007) Conjugated primary bile salts reduce permeability of endotoxin through intestinal epithelial cells and synergize with phosphatidylcholine in suppression of inflammatory cytokine production. Crit Care Med 35:2367–2374CrossRef
134.
Lorenzo-Zúñiga V, Bartolí R, Planas R et al (2003) Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 37(3):551–557. doi:10.​1053/​jhep.​2003.​50116 CrossRef
135.
Sherriff JL, O’Sullivan TA, Properzi C et al (2016) Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes. Adv Nutr 7(1):5–13CrossRef
136.
Y-m Chen, Liu Y, R-f Zhou et al (2016) Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with nonalcoholic fatty liver disease in adults. Sci Rep 6:19076. doi:10.​1038/​srep19076 CrossRef
137.
Gao X, Liu X, Xu J et al (2014) Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng 118:476–481CrossRef
138.
Shih DM, Wang Z, Lee R et al (2015) Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res 56:22–37CrossRef
139.
Raubenheimer PJ, Nyirenda MJ, Walker BR (2006) A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes 55:2015–2020CrossRef
140.
141.
Guerrerio AL, Colvin RM, Schwartz AK et al (2012) Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr 95:892–900CrossRef
142.
Spencer MD, Hamp TJ, Reid RW et al (2011) Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140(3):976–986CrossRef
143.
144.
Fava F, Gitau R, Griffin BA et al (2013) The type and quantity of dietary fat and carbohydrate alter fecal microbiome and short-chain fatty acid excretion in a metabolic syndrome ‘at-risk’ population. Int J Obes 37:216–223CrossRef
145.
Xu Z, Knight R (2015) Dietary effects on human gut microbiome diversity. Br J Nutr 113:S1–S5CrossRef
146.
National Institute for Health and Care Excellence (2016) Nonalcoholic fatty liver disease: assessment and management. NICE Guideline NG49, Methods, evidence and recommendations. ISBN: 978-1-4731-1955-0. http://​nice.​org.​uk/​guidance/​ng49
147.
Schwenger KJP, Allard JP (2014) Clinical approaches to nonalcoholic fatty liver disease. World J Gastroenterol 20(7):1712–1723CrossRef
148.
Zhang C, Li S, Yang L et al (2013) Structural modulation of gut microbiota in life-long calorie-restricted mice. Nat Commun 4:2163. doi:10.​1038/​ncomms3163
149.
Santacruz A, Marcos A, Wärnberg J et al (2009) Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity 17:1906–1915CrossRef
150.
Kim MS, Hwang SS, Park EJ et al (2013) Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 5:765–775CrossRef
151.
Cotillard A, Kennedy SP, Kong LC et al (2013) Dietary intervention impact on gut microbial gene richness. Nature 29(500):585–588CrossRef
152.
153.
Obregon-Tito AJ, Tito RY, Metcalf JL et al (2015) Subsistence strategies in traditional societies distinguish gut microbiomes. Nat Commun 6:6505CrossRef
154.
155.
Wu GD, Chen J, Hoffmann C et al (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334:105–108CrossRef
156.
De Filippo C, Cavalieri D, Di Paola M et al (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. PNAS 107(33):14691–14696CrossRef
157.
158.
De Wit N, Derrien M, Bosch-Vermeulen H et al (2012) Saturated fat stimulates obesity and hepatic steatosis and affects gut microbiota composition by an enhanced overflow of dietary fat to the distal intestine. Am J Physiol Gastrointest Liver Physiol 303:589–599CrossRef
159.
Caesar R, Tremaroli V, Kovatcheva-Datchary P et al (2015) Crosstalk between gut microbiota and dietary lipids aggravates WAT Inflammation through TLR signaling. Cell Metab 22(4):658–668CrossRef
160.
Brinkworth GD, Noakes M, Clifton PM et al (2009) Comparative effects of very low-carbohydrate, high-fat and highcarbohydrate, low-fat weight-loss diets on bowel habit and fecal short-chain fatty acids and bacterial populations. Br J Nutr 101:1493–1502CrossRef
161.
Duncan SH, Belenguer A, Holtrop G et al (2007) Reduced dietary intake of carbohydrate, by obese subjects, results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 73:1073–1078CrossRef
162.
Lopez-Legarrea P, Fuller NR, Zulet MA et al (2014) The influence of Mediterranean, carbohydrate and high protein diets on gut microbiota composition in the treatment of obesity and associated inflammatory state. Asia Pac J Clin Nutr 23(3):360–368
163.
Hooda S, Boler BMV, Kerr KR et al (2013) The gut microbiome of kittens is affected by dietary protein: carbohydrate ratio and associated with blood metabolite and hormone concentrations. Br J Nutr 109(9):1637–1646CrossRef
164.
Smith EA, Macfarlane GT (1996) Studies on amine production in the human colon: enumeration of amine forming bacteria and physiological effects of carbohydrate and pH. Anaerobe 2(5):285–297CrossRef
165.
Russell WR, Gratz SW, Duncan SH et al (2011) Highprotein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am J Clin Nutr 93(5):1062–1072CrossRef
166.
Cani PD, Neyrinck AM, Fava F et al (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50:2374–2383CrossRef
167.
Reddy BS, Weisburger JH, Wynder EL (1995) Effects of high risk and low risk diets for colon carcinogenesis on fecal microflora and steroids in man. J Nutr 105(7):878–884CrossRef
168.
Matijasic BB, Obermajer T, Lipoglavsek L et al (2014) Association of dietary type with fecal microbiota in vegetarians and omnivores in Slovenia. Eur J Nutr 53(4):1051–1064CrossRef
Metadaten
Titel
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis
verfasst von
Fabiana de Faria Ghetti
Daiane Gonçalves Oliveira
Juliano Machado de Oliveira
Lincoln Eduardo Villela Vieira de Castro Ferreira
Dionéia Evangelista Cesar
Ana Paula Boroni Moreira
Publikationsdatum
05.09.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nutrition / Ausgabe 3/2018
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-017-1524-x

Weitere Artikel der Ausgabe 3/2018

European Journal of Nutrition 3/2018 Zur Ausgabe

Original Contribution

Attenuation of liver cancer development by oral glycerol supplementation in the rat

Original Contribution

Amino acid starvation-induced autophagy is involved in reduced subcutaneous fat deposition in weaning piglets derived from sows fed low-protein diet during gestation and lactation

Letter to the Editor

Research interactions between academia and food companies: how to improve transparency and credibility of an inevitable liaison

Review

Reduced energy availability: implications for bone health in physically active populations

Original Contribution

Erythrocyte fatty acid composition of Nepal breast-fed infants

Original Contribution

Prospective association between adherence to the Mediterranean diet and risk of depressive symptoms in the French SU.VI.MAX cohort

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise